TV ad for the new lubricant eye drops opens with a man in a desert background saying: "Imagine a world without moisture. For millions of people with dry, scratchy eyes, this is how their world feels...Now there's new Visine Tears for dry eyes, with a unique tears formula not found in other leading brands." Over a likeness of a dry, cracked-looking eye, the narrator says the product "soothes dry scratchy eyes and makes them feel moist and comfortable in seconds, and it's safe to use as often as you need." The ad concludes with the narrator stating, "Discover a world of comfort with new Visine Tears. It gets the dry out." Pfizer also is promoting the product to eye care professionals through sampling and journal print ads. The product was launched in mid-January ("The Tan Sheet" Jan. 18, p. 4)
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.
Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.
At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.
